BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 22189395)

  • 1. The molecular classification of medulloblastoma: driving the next generation clinical trials.
    Leary SE; Olson JM
    Curr Opin Pediatr; 2012 Feb; 24(1):33-9. PubMed ID: 22189395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features.
    Kool M; Koster J; Bunt J; Hasselt NE; Lakeman A; van Sluis P; Troost D; Meeteren NS; Caron HN; Cloos J; Mrsić A; Ylstra B; Grajkowska W; Hartmann W; Pietsch T; Ellison D; Clifford SC; Versteeg R
    PLoS One; 2008 Aug; 3(8):e3088. PubMed ID: 18769486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes.
    Sharma T; Schwalbe EC; Williamson D; Sill M; Hovestadt V; Mynarek M; Rutkowski S; Robinson GW; Gajjar A; Cavalli F; Ramaswamy V; Taylor MD; Lindsey JC; Hill RM; Jäger N; Korshunov A; Hicks D; Bailey S; Kool M; Chavez L; Northcott PA; Pfister SM; Clifford SC
    Acta Neuropathol; 2019 Aug; 138(2):309-326. PubMed ID: 31076851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-omics analysis of intertumoral heterogeneity within medulloblastoma uncharted-pathway subtypes.
    Li Z; Wei Y; Shao Y; Tang L; Gong J
    Brain Tumor Pathol; 2021 Jul; 38(3):234-242. PubMed ID: 34180021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis.
    Thompson EM; Hielscher T; Bouffet E; Remke M; Luu B; Gururangan S; McLendon RE; Bigner DD; Lipp ES; Perreault S; Cho YJ; Grant G; Kim SK; Lee JY; Rao AAN; Giannini C; Li KKW; Ng HK; Yao Y; Kumabe T; Tominaga T; Grajkowska WA; Perek-Polnik M; Low DCY; Seow WT; Chang KTE; Mora J; Pollack IF; Hamilton RL; Leary S; Moore AS; Ingram WJ; Hallahan AR; Jouvet A; Fèvre-Montange M; Vasiljevic A; Faure-Conter C; Shofuda T; Kagawa N; Hashimoto N; Jabado N; Weil AG; Gayden T; Wataya T; Shalaby T; Grotzer M; Zitterbart K; Sterba J; Kren L; Hortobágyi T; Klekner A; László B; Pócza T; Hauser P; Schüller U; Jung S; Jang WY; French PJ; Kros JM; van Veelen MC; Massimi L; Leonard JR; Rubin JB; Vibhakar R; Chambless LB; Cooper MK; Thompson RC; Faria CC; Carvalho A; Nunes S; Pimentel J; Fan X; Muraszko KM; López-Aguilar E; Lyden D; Garzia L; Shih DJH; Kijima N; Schneider C; Adamski J; Northcott PA; Kool M; Jones DTW; Chan JA; Nikolic A; Garre ML; Van Meir EG; Osuka S; Olson JJ; Jahangiri A; Castro BA; Gupta N; Weiss WA; Moxon-Emre I; Mabbott DJ; Lassaletta A; Hawkins CE; Tabori U; Drake J; Kulkarni A; Dirks P; Rutka JT; Korshunov A; Pfister SM; Packer RJ; Ramaswamy V; Taylor MD
    Lancet Oncol; 2016 Apr; 17(4):484-495. PubMed ID: 26976201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clustering of self-organizing map identifies five distinct medulloblastoma subgroups.
    Cao C; Wang W; Jiang P
    Cancer Biomark; 2016; 16(3):327-32. PubMed ID: 26889815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma.
    Remke M; Hielscher T; Korshunov A; Northcott PA; Bender S; Kool M; Westermann F; Benner A; Cin H; Ryzhova M; Sturm D; Witt H; Haag D; Toedt G; Wittmann A; Schöttler A; von Bueren AO; von Deimling A; Rutkowski S; Scheurlen W; Kulozik AE; Taylor MD; Lichter P; Pfister SM
    J Clin Oncol; 2011 Oct; 29(29):3852-61. PubMed ID: 21911727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.
    Schwalbe EC; Lindsey JC; Nakjang S; Crosier S; Smith AJ; Hicks D; Rafiee G; Hill RM; Iliasova A; Stone T; Pizer B; Michalski A; Joshi A; Wharton SB; Jacques TS; Bailey S; Williamson D; Clifford SC
    Lancet Oncol; 2017 Jul; 18(7):958-971. PubMed ID: 28545823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medulloblastoma: From Myth to Molecular.
    Ramaswamy V; Taylor MD
    J Clin Oncol; 2017 Jul; 35(21):2355-2363. PubMed ID: 28640708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medulloblastomas in adults: prognostic factors and lessons from paediatrics.
    Fellay CN; Frappaz D; Sunyach MP; Franceschi E; Brandes AA; Stupp R
    Curr Opin Neurol; 2011 Dec; 24(6):626-32. PubMed ID: 22027544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial.
    Robinson GW; Rudneva VA; Buchhalter I; Billups CA; Waszak SM; Smith KS; Bowers DC; Bendel A; Fisher PG; Partap S; Crawford JR; Hassall T; Indelicato DJ; Boop F; Klimo P; Sabin ND; Patay Z; Merchant TE; Stewart CF; Orr BA; Korbel JO; Jones DTW; Sharma T; Lichter P; Kool M; Korshunov A; Pfister SM; Gilbertson RJ; Sanders RP; Onar-Thomas A; Ellison DW; Gajjar A; Northcott PA
    Lancet Oncol; 2018 Jun; 19(6):768-784. PubMed ID: 29778738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Subgrouping of Medulloblastoma: Impact Upon Research and Clinical Practice.
    Gupta T; Shirsat N; Jalali R
    Curr Pediatr Rev; 2015; 11(2):106-19. PubMed ID: 26133181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical implications of medulloblastoma subgroups.
    Northcott PA; Korshunov A; Pfister SM; Taylor MD
    Nat Rev Neurol; 2012 May; 8(6):340-51. PubMed ID: 22565209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetics of medulloblastoma: clues for novel therapies.
    Onvani S; Etame AB; Smith CA; Rutka JT
    Expert Rev Neurother; 2010 May; 10(5):811-23. PubMed ID: 20420498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Desmoplastic/nodular medulloblastomas (DNMB) and medulloblastomas with extensive nodularity (MBEN) disclose similar epigenetic signatures but different transcriptional profiles.
    Korshunov A; Sahm F; Okonechnikov K; Ryzhova M; Stichel D; Schrimpf D; Casalini B; Sievers P; Meyer J; Zheludkova O; Golanov A; Lichter P; Jones DTW; Pfister SM; Kool M; von Deimling A
    Acta Neuropathol; 2019 Jun; 137(6):1003-1015. PubMed ID: 30826918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The proteomic analysis shows enrichment of RNA surveillance pathways in adult SHH and extensive metabolic reprogramming in Group 3 medulloblastomas.
    Kp M; Kumar A; Biswas D; Moiyadi A; Shetty P; Gupta T; Epari S; Shirsat N; Srivastava S
    Brain Tumor Pathol; 2021 Apr; 38(2):96-108. PubMed ID: 33438046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medulloblastoma-translating discoveries from the bench to the bedside.
    Gajjar AJ; Robinson GW
    Nat Rev Clin Oncol; 2014 Dec; 11(12):714-22. PubMed ID: 25348790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Approaches in Targeted Therapy for Medulloblastoma in Children.
    Maier H; Dalianis T; Kostopoulou ON
    Anticancer Res; 2021 Apr; 41(4):1715-1726. PubMed ID: 33813375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Advances in Pediatric Medulloblastoma.
    Jackson K; Packer RJ
    Curr Neurol Neurosci Rep; 2023 Dec; 23(12):841-848. PubMed ID: 37943476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of the molecular genetics and chemotherapeutic treatment of adult and paediatric medulloblastoma.
    Newton HB
    Expert Opin Investig Drugs; 2001 Dec; 10(12):2089-104. PubMed ID: 11772307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.